Efficacy Of Mycophenolate Mofetil For The Treatment Of Systemic Sclerosis Related Interstitial Lung Disease:A Meta-Analysis

Objects: The aim of this meta-analysis was to evaluate the clinical efficacy of mycophenolate mofetil in the treatment of systemic sclerosis-related interstitial lung disease.Besides,we made an assumption that mycophenolate mofetil(MMF)would be as effective as cyclophosphamide(CYC).Methods: A systematic literature search was conducted by a computer to collect clinical trials which met the inclusion criteria.Meta-analysis was performed using Rev Man 5.3 software for homogeneous studies.Results: Eleven studies including 323 cases were reviewed.There was no statistical difference in lung function tests before and after treatment,including forced vital capacity(FVC)% of the predicted normal value(pred)(weighted mean difference= 3.19,95% confidence interval(CI):-0.61 to6.99,P = 0.10).Diffusion capacity for carbon monoxide(DLCO)% pred(weighted mean difference=-0.62,95% CI-4.46 to3.23,P= 0.75).Vital Capacity(VC)% pred(weighted mean difference=5.59,95% CI:-4.22to15.40,P = 0.26).Forced Expiratory Volume in the first second(FEV1)%pred(weighted mean difference=4.95,95% CI:-12.69 to22.59,P = 0.58)。Besides,there was no significant difference in the change of forced vital capacity after treatment between mycophenolate mofetil and cyclophosphamide(weighted mean difference=0.28,95% CI:-0.10 to 0.66,P=0.15).Conclusions: Meta-analysis data suggest that mycophenolate mofetil is an effective treatment for systemic sclerosis related interstitial lung disease,which contributes to the stability of lung function and prevents deterioration.Compared with cyclophosphamide,mycophenolate mofetil has similar efficacy,better tolerance,lower incidence and lower severity of adverse reactions,it may be used as a new treatment option.